Porfolio

Scientific writing (2020-2025)

Steuerwald T, Blair D, Cowan E, Isbell M, S SB, Firmat J, Barriere N, Tatoud R. Improving the efficiency of the regulatory approvals of HIV in vitro diagnostics in low- and middle-income countries: Perspective of the IAS Industry Liaison Forum diagnostic partners. PLOS Global Public Health (2025) 5(4):e0004169.

Tatoud R, Lévy Y, Grand RL, Alcami J, Barbareschi G, Brander C, et al. In danger: HIV vaccine research and development in Europe. PLOS Global Public Health 2025 Apr 8;5(4):e0004364.

Tatoud R, Brander C, Hwang C, Kennelly J, Lu S, O’Neil K, et al. Biotech’s role in advancing HIV vaccine development. Emerging Microbes & Infections. (2024) 13(1):2384460.

Tatoud R, Jones RB, Dong K, Ndung’u T, Deeks S, Tiemessen CT. Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientists. Journal of Virus Eradication. 2024 10(1):100364.

Prudden H, Tatoud R, Slack C, Shattock R, Anklesaria P, Bekker LG, et al. Experimental Medicine for HIV Vaccine Research and Development. Vaccines (2023) May 11(5):970.

Prudden HJ, Tatoud R, Janes H, Wallace S, Miller V, Bekker LG, Donnell D. Perspectives on Design Approaches for HIV Prevention Efficacy Trials. AIDS Res Hum Retroviruses (2023).

Tatoud, R., Prudden, H, Slack, C., Shattock, R., Anklesaria, P., Bekker, L.-G., Buchbinder, S. Experimental Medicine for HIV Vaccine Research and Development. Vaccines (2023), 11, 970.

Henderson M, Fidler S, Mothe B, Grinsztejn B, Haire B, Collins S, Lau JSY, Luba M, Sanne I, Tatoud R, Deeks S and Lewin SR. (2022), Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. J Int AIDS Soc. 25: e25882.

Tatoud R, Snow W and Esparza J (2021), A transformed global enterprise for an HIV vaccine. J Int AIDS Soc., 24: e25822.

Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung’u T, Russell N, Johnson J, Luba M, Fauci AS, Morris L, Pantaleo G, Buchbinder S, Gray G, Vekemans J, Kim JH, Levy Y, Corey L, Shattock R, Makanga M, Williamson C, Dieffenbach C, Goodenow MM, Shao Y, Staprans S, Warren M, Johnston MI. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020 Feb 1;395(10221):384-388.

Capacity Building and Research Leadership Development in Africa
Various institutions, 2023–2025

I have contributed to several initiatives focused on strengthening research capacity and leadership among early-career researchers in Africa. My work spans both scientific and advocacy training, as well as institutional leadership development. These programmes reflect my commitment to advancing equitable, African-led research systems through targeted capacity building, mentorship, and institutional engagement.

• IAS Research-for-Cure Academy (2023, 2024, 2025)
  Co-designed and delivered training modules aimed at enhancing the scientific knowledge and research skills of emerging HIV cure researchers.

• IAS Vaccine Science Academy (2023, 2024, 2025)
  Contributed to the development and facilitation of training focused on the science of HIV vaccines, targeting early-stage investigators in sub-Saharan Africa.

• IAS Vaccine Advocacy Academy (2025)
  Supported the design and delivery of advocacy training to strengthen regional leadership in vaccine research and equitable access.

• Africa Research Excellence Fund (AREF): EXCELL Programme
  Participated in the pilot phase of AREF’s EXCELL Researcher and Leadership Development initiative, designed to foster both individual and institutional research leadership. I subsequently took part in the full EXCELL Programme, which aims to build long-term capacity for global health research in Africa by transforming the leadership capabilities of researchers and partner institutions.

Monoclonal Antibodies: Emerging Applications for Global Health
World Health Organization, 2024

I supported a WHO project aimed at advancing the strategic use of monoclonal antibodies (mAbs) for global health. The objectives were to support targeted R&D investment, promote equitable access, and articulate the client’s position in a rapidly evolving field. This involved identifying key opportunities and gaps in the current landscape, and developing actionable recommendations to guide policy and programme responses.

Potential benefits and limitations of mRNA technology for vaccine research and development for infectious diseases and virus-induced cancers

WHO Science Council on mRNA Technology
World Health Organization, 2023

I supported the work of the WHO Science Council exploring the added value of mRNA technology for the prevention of infectious diseases. My role included conducting a desk and literature review, designing and coordinating an online expert consultation, and drafting the final report. This work informed the Council’s deliberations on the strategic role of mRNA platforms in future public health responses.

Strategic Design and Delivery of Scientific Events
Various clients and partnerships

I provide comprehensive event organisation services, from initial concept to final reporting, for both virtual and in-person formats. My role typically covers content development, event design, speaker identification and engagement, agenda and script preparation, supporting materials, logistical coordination, chairing, and reporting. These events are designed to foster inclusive dialogue, promote knowledge exchange, and inform practice in the field of global health research.

Selected examples include:

• Virtual Workshop: “Design Approaches for Current and Future HIV Prevention Efficacy Trials”

  A multi-month virtual series featuring 19 presentations and 6 panel discussions, exploring methodological and regulatory issues in HIV prevention trial design.

• Three-Part Virtual Series: Experimental Medicine for Preventative HIV Vaccines
  A technical consultation on the use of experimental medicine trials for accelerating HIV vaccine development, culminating in a peer-reviewed publication.

Inclusion of People Living with HIV in Non-HIV Clinical Research
European AIDS Treatment Group (EATG), 2022

I led the development of a position paper advocating for the inclusion of people living with HIV in non-HIV clinical research. This work addressed the persistent exclusion of this population from broader research agendas and proposed clear recommendations for more inclusive trial practices. To support uptake and policy impact, I also designed an accompanying advocacy strategy aimed at guiding the formulation and adoption of inclusive research guidelines, ultimately contributing to improved health outcomes for people living with HIV.

Revision of the IAVI Vaccine Literacy Library
International AIDS Vaccine Initiative (IAVI), 2022

Together with Rebekah Webb, I led the update and expansion of the IAVI Vaccine Literacy Library, originally developed in 2008. The revised library provides accessible, plain-language information on HIV, tuberculosis, and Lassa virus vaccines, tailored for use by IAVI staff at clinical trial sites. To support training and knowledge dissemination, the library is accompanied by an 80-slide PowerPoint deck. The visual design was developed in collaboration with Anthea Duce, ensuring clarity and usability across diverse settings.

Lay Summary of the HIV Cure Global Scientific Strategy
International AIDS Society (IAS), 2021

As part of the International AIDS Society’s 2021 update of the HIV Cure Global Scientific Strategy, I coordinated and co-authored a detailed lay summary: Research Priorities for an HIV Cure: IAS Global Scientific Strategy 2021 – The Science in Context. This resource was developed to make complex scientific content accessible to non-specialist audiences, supporting wider engagement with cure research priorities among communities, advocates, and policy stakeholders.